Pfizer, BioNTech begin virus vaccine trial
Pfizer Inc and BioNTech SE said they have begun delivering doses of their experimental coronavirus vaccines for initial human testing in the U.S.
- The U.S. drugmaker and German partner said if the vaccine proves to be safe and effective in trials, it could potentially be ready for wide U.S. distribution by the end of the year, shaving several years off the typical vaccine development timeline.
- The vaccine, which uses messenger RNA (mRNA) technology, has the potential to be among the first vaccines against the virus.
- There are currently no approved treatments or vaccines for the new coronavirus, though some drugs are being used on patients under an emergency use authorisation.
- The trial will initially aim to test different dosing regimens of four potential vaccine candidates on around 360 healthy volunteers divided into a younger cohort and a group of seniors.